Longenesis addresses the critical bottlenecks in clinical research: siloed data, regulatory compliance, and poor patient engagement. Their deck highlights two core products—Curator for metadata-driven data discovery and Engage for dynamic consent and real-world data collection. By operating on anonymized metadata rather than raw patient identifiers, they bypass traditional EMR integration hurdles. The deck demonstrates strong early traction with 100% year-over-year revenue growth in 2021 and partnerships with major entities like Medtronic and Intel. However, the presentation lacks a tradition…
Key takeaways
- The company operates a two-pillar product strategy consisting of Longenesis Curator for data sharing and Longenesis Engage for patient interaction (Slide 19).
- Longenesis claims that 86% of clinical trials are delayed, often due to difficulties in identifying and engaging patients across multiple institutions (Slide 13).
- The Curator platform utilizes anonymized statistical metadata to ensure health data stays local and avoids PHI access or EMR integration (Slide 21).
- Financial performance shows a jump from €110,000 in 2020 to €280,000 in 2021, with a forecast of €4,000,000 by 2025 (Slide 31).
- The company reached a €7.3m pre-money valuation following a $1.2m Seed round in Q2 2021 and a $540k bridge round in Q2 2022 (Slide 29).
- Traction metrics include 30 data publishers on the Curator platform and a reduction in deployment time for Engage to 11 days for recent projects (Slide 33).
- The advisory board features high-profile industry figures, including the CEO of Insilico Medicine and a Senior VP from Foundation Medicine (Slide 11).
- The deck includes specific case studies involving pandemic-induced economic shock studies and Long COVID symptom tracking (Slides 37, 39).
Executive Summary
Longenesis is a health-tech company focused on streamlining the intersection of healthcare providers and life sciences researchers. Their pitch deck, dated April 2022, outlines a sophisticated approach to unlocking medical data silos through metadata curation and enhancing patient participation via digital consent tools. The deck serves as a progress report and a forward-looking growth plan, highlighting a transition from pilot projects to international scaling. While the deck is heavy on product architecture and ecosystem validation, it lacks a traditional executive team slide, relying instead on a high-powered advisory board to establish leadership credibility.
Slide 1-5: Introduction and Mission
The deck opens with a title slide identifying the presentation as an "Investors Pitch Deck" for TechChill in April 2022. Slide 3 is a simple "About Us" section header. Slide 5 defines the company's core mission: "Bridging healthcare and life sciences." The company positions itself as a provider of solutions for collecting, analyzing, and utilizing medical data. They emphasize an "end-to-end, intuitive toolkit for Data Discovery and Patient-Centric Engagement," underpinned by "Privacy- and Ethics-by-Design."
Slide 7-11: Validation and Governance
Slide 7, titled "Why Us – 2/2," lists four pillars of competitive advantage: backing by sector leaders (Insilico Medicine, Bitfury Group), wide team expertise, a global network of partners, and industry awards. Slide 9 showcases "Recent Achievements," including being a TechChill 2021 winner and an EIT Health Headstart COVID winner. Media features in Wired, Reuters, and Forbes are also noted. Slide 11 introduces the Advisory Board, which includes Alex Zhavoronkov (CEO of Insilico Medicine), Miro Venturi (SVP of Foundation Medicine), Dennis Bronnikov (formerly of Roche), and Leesa Soulodre (R3i Ventures). Notably, the actual operational management team is not pictured in this subset of slides.
Slide 13-15: The Problem and the Two-Pillar Solution
Slide 13 identifies the "Main Challenges": siloed/unstructured data, regulatory privacy risks, and lack of patient engagement. A key metric is cited: "86% of trials are delayed." The slide argues that 9 out of 10 clinical sites are overlooked in the selection process. Slide 15 introduces the first product pillar: Longenesis Curator . This platform is described as a digital ecosystem that streamlines data sharing by allowing researchers to find anonymized patient data without moving the data from its original owner. The slide stresses that "All data remains localized," meaning no PHI is shared with third-party servers.
Slide 17-19: Value Proposition and Ecosystem
Slide 17 presents a "Value Creation Opportunity for Pharma" using a graph that maps the drug life cycle against cost and revenue. It suggests that Curator reduces R&D costs and accelerates market launch, while the second product, Longenesis Engage , increases market share through sustained engagement. Slide 19 visualizes the "Ecosystem," showing how Data Publishers (Biobanks, Hospitals) connect to Curator for data discovery and Engage for patient interaction, while Partners/Sponsors (Pharma, AI companies) interact with both to drive Real World Data (RWD) collection.
Slide 21-25: Product Deep Dive
Slide 21 explains "Why Metadata." It shows a UI mockup of the Curator platform, which allows users to filter by gender, date of birth, and diagnosis. The platform operates on "anonymized statistical patient information" without EMR integration. Slide 23 provides an overview of Engage functionalities, highlighting dynamic consent management and RWD collection. It lists deployment examples such as a National Population Genome program in the Middle East and COVID-19 population studies. Slide 25 focuses on "Dynamic E-Consent Management," describing it as a real-time instrument for consent audits that empowers patients to decide how their data is used.
Slide 27-29: Regulatory Status and Traction
Slide 27 outlines the regulatory framework, stating that Engage adheres to HIPAA, GDPR, and PIPA, while Curator avoids PHI entirely. Both utilize regional cloud deployments. Slide 29, "Our Journey So Far," provides a timeline. Founded in 2017, the company raised a $1.2m Seed round in Q2 2021 and a $540k bridge round in Q2 2022, reaching a $7.3m pre-money valuation. Achievements include 100% revenue growth in 2021 and partnerships with Medtronic, Intel, and Bayer. The slide also mentions a move from Hong Kong to the US in preparation for a Series A.
Slide 31-33: Financials and Scalability
Slide 31 displays "Financial Performance." Actual revenue was €110,000 in 2020 and €280,000 in 2021. The forecast shows aggressive growth: €660,000 in 2022, €1,220,000 in 2023, €2,500,000 in 2024, and €4,000,000 in 2025. Specific 2021 results include a €140k contract with Group 42 Healthcare. Slide 33, "Customer Success & Scalability," provides operational metrics: 30 data publishers on Curator and a reduction in Engage deployment time from 35 days to 11 days for the most recent projects.
Slide 35-41: Case Studies
The final section of the deck provides concrete examples of the technology in use. Slide 37 details a study on pandemic-induced economic shocks with the FORTHEM Alliance. Slide 39 describes tracking Long COVID symptoms with the Children's University Hospital Latvia, where Engage enabled patient triage and Curator provided proximity to vital data. Slide 41 highlights a "Federating Learning" project for a major pharma client in pediatrics, where Curator was used to discover data for local AI model training without violating patient permissions.
What Works Well in This Deck
Clear Product Differentiation: The distinction between Curator (data discovery) and Engage (patient interaction) is well-defined and visually consistent throughout the deck. · Regulatory De-risking: By emphasizing that the platform operates on metadata and localized data (Slide 21), the company addresses the primary concern of healthcare investors: data privacy and the nightmare of EMR integration. · Concrete Traction: The inclusion of specific revenue figures, partner names like Intel and Medtronic, and actual contract values (Slide 31) provides a level of transparency often missing in early-stage decks. · Case Study Depth: The appendix slides (37-41) move beyond theory to show how the platform handles complex, real-world scenarios like Long COVID and federated AI training.
What Is Missing or Could Be Improved
The Management Team: While the Advisory Board (Slide 11) is impressive, the deck does not introduce the founders or the executive team. Investors fund people, and the absence of the core team is a significant omission. · The "Ask": There is no slide explicitly stating how much capital the company is currently seeking or how they intend to spend it. While the funding history is clear (Slide 29), the current investment opportunity is not. · Unit Economics: The deck shows top-line revenue growth and forecasts, but it does not detail the cost of customer acquisition (CAC), lifetime value (LTV), or the specific pricing model (SaaS vs. per-project). · Competitive Landscape: There is no direct comparison to other players in the clinical trial data space. A "competitor matrix" would help clarify where Longenesis sits relative to legacy CROs or other health-tech startups.
Founder Takeaways
Use Metadata to Bypass Integration Hurdles: Longenesis provides a masterclass in positioning. By focusing on metadata curation (Slide 21), they solve the "data silo" problem without the technical and legal friction of moving raw patient records. Founders in highly regulated spaces should look for similar "low-friction" entry points.
Validate with Heavyweights: The "Our Journey So Far" slide (Slide 29) uses logos effectively. By grouping Intel, Bayer, and Medtronic under "Achievements," they signal that their technology has passed the rigorous procurement and security audits of global giants.
Quantify Operational Efficiency: Slide 33 shows a reduction in deployment time from 35 days to 11 days. This is a powerful metric for a B2B platform, as it demonstrates that the product is becoming easier to implement as the company scales, which is a key indicator of future profitability.
Leverage a Strong Advisory Board: If your operational team is young or lacks deep industry exits, follow the Longenesis model of highlighting a high-tier Advisory Board (Slide 11) to provide institutional credibility and industry connections.
Frequently asked questions
- What specific problem does Longenesis solve in clinical trials?
- According to slide 13, Longenesis addresses the fact that 86% of clinical trials are delayed. The primary causes identified are siloed and unstructured data, time-consuming data organization, regulatory privacy risks, and the difficulty of engaging patients. They specifically note that 9 out of 10 clinical sites are overlooked during the selection process due to these technological and regulatory barriers.
- How does Longenesis handle sensitive patient data (PHI)?
- Longenesis emphasizes a 'Privacy-by-Design' approach. Slide 21 states that their Curator platform operates with anonymized statistical patient information without accessing Protected Health Information (PHI). Data remains localized to its owners and is never shared with third-party servers or stored in centralized databases. This allows them to function without complex EMR integrations or data ingestion.
- What are the core functionalities of the 'Engage' platform?
- As detailed on slide 23, Engage provides end-to-end dynamic consent management and Real World Data (RWD) collection. It is designed to be integrated into existing interfaces or used as a white-labeled standalone solution. It facilitates participant-centric interfaces for questionnaires, risk assessments, and personalized reporting, which the company claims leads to higher retention rates and faster insights.
- What is the company's current financial status and valuation?
- Slide 29 notes that Longenesis was founded in 2017 and raised a $1.2m Seed round in Q2 2021, followed by a $540k bridge round in Q2 2022. These rounds established a $7.3m USD pre-money valuation. Slide 31 shows actual revenue of €280,000 for 2021, representing over 100% growth from the previous year.
- Who are the key partners and customers mentioned in the deck?
- The deck lists several high-profile partners and achievements on slides 9 and 29, including Medtronic, Intel, Bayer, Alexion, and Lilly. They also highlight a 140k EUR project with Group 42 Healthcare in the UAE and collaborations with the Children's University Hospital Latvia and the FORTHEM Alliance of European universities.
